Molecular Assessment for Gastro-Esophageal Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-100
SponsorKU Leuven
About this trial
The goal of this minimally invasive interventional study is to learn if oncometabolic biomarkers, detected in the exhaled breath and blood can identify early-stage gastro-oesophageal cancer in patient at risk for gastro-oesophageal cancer.
The main questions this study aims to answer:
Are oncometabolites proficient and reproducible enough to function as diagnostic biomarkers? Can these biomarkers identify early-stage gastro-esophageal cancer? Researchers will compare participants with gastro-oesophageal cancer to healthy controls and participants with Barrett's esophagus to detect meaningful differences between the groups.
Participants will provide a breath and blood sample during their routine standard of care visits.
Eligibility criteria
Qualifiers
Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any breath or blood analysis
>18 years old
Barrett's esophagus or treatment naïve gastro-esophageal cancer stage I to IV
Voluntary healthy controls
Disqualifiers
<18 years old
Active other cancer than gastro-esophageal cancer
Prior cancer treated <3 years ago
Hepatic dysfunction/liver failure (MELT >7)
Trial design
Treatments tested in this trial
- Breath analysis
- Blood analysis
Treatment groups
1,000 Participants
are divided into 3 treatment groupsSponsors and collaborators
KU Leuven
Lead sponsor
Universitaire Ziekenhuizen KU Leuven
Sponsor institution
Source ClinicalTrials.gov